Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 22
Filter
1.
Cytogenet Genome Res ; 162(1-2): 28-33, 2022.
Article in English | MEDLINE | ID: mdl-35477180

ABSTRACT

A palette of copy number changes in long-term epilepsy-associated tumors (LEATs) have been reported, but the data are heterogeneous. To better understand the molecular basis underlying the development of LEATs, we performed array-comparative genomic hybridization analysis to investigate chromosomal imbalances across the entire genome in 8 cases of LEATs. A high number of aberrations were found in 4 patients, among which deletions predominated. Both whole-chromosome and regional abnormalities were observed, including monosomy 19, deletion of 1p, deletions of 4p, 12p, and 22q, and gain of 20p. The common altered regions are located mainly on chromosomes 19 and 4p, identifying genes potentially involved in biological processes and cellular mechanisms related to tumorigenesis. Our study highlights new genomic alterations and reinforces others previously reported, offering new molecular insights that may help in diagnosis and therapeutic decision-making.


Subject(s)
Epilepsy , Neoplasms , Chromosome Aberrations , Comparative Genomic Hybridization , Epilepsy/genetics , Genomics , Humans , Monosomy , Nucleic Acid Hybridization
2.
Neuropathology ; 42(6): 467-482, 2022 Dec.
Article in English | MEDLINE | ID: mdl-35844095

ABSTRACT

Low-grade neuroepithelial tumors (LNETs) represent an important group of central nervous system neoplasms, some of which may be associated to epilepsy. The concept of long-term epilepsy-associated tumors (LEATs) includes a heterogenous group of low-grade, cortically based tumors, associated to drug-resistant epilepsy, often requiring surgical treatment. LEATs entities can sometimes be poorly discriminated by histological features, precluding a confident classification in the absence of additional diagnostic tools. This study aimed to provide an updated review on the genomic findings and DNA methylation profiling advances in LNETs, including histological entities of LEATs. A comprehensive search strategy was conducted on PubMed, Embase, and Web of Science Core Collection. High-quality peer-reviewed original manuscripts and review articles with full-text in English, published between 2003 and 2022, were included. Results were screened based on titles and abstracts to determine suitability for inclusion, and when addressed the topic of the review was screened by full-text reading. Data extraction was performed through a qualitative content analysis approach. Most LNETs appear to be driven mainly by a single genomic abnormality and respective affected signaling pathway, including BRAF p.V600E mutations in ganglioglioma, FGFR1 abnormalities in dysembryoplastic neuroepithelial tumor, MYB alterations in angiocentric glioma, BRAF fusions in pilocytic astrocytoma, PRKCA fusions in papillary glioneuronal tumor, between others. However, these molecular alterations are not exclusive, with some overlap amongst different tumor histologies. Also, clustering analysis of DNA methylation profiles allowed the identification of biologically similar molecular groups that sometimes transcend conventional histopathological classification. The exciting developments on the molecular basis of these tumors reinforce the importance of an integrative histopathological and (epi)genetic classification, which can be translated into precision medicine approaches.


Subject(s)
Brain Neoplasms , Epilepsy , Ganglioglioma , Glioma , Neoplasms, Neuroepithelial , Child , Humans , DNA Methylation , Neoplasms, Neuroepithelial/pathology , Ganglioglioma/pathology , Glioma/genetics , Brain Neoplasms/pathology , Epilepsy/genetics , Epilepsy/pathology
3.
Eur Neurol ; 79(1-2): 13-20, 2018.
Article in English | MEDLINE | ID: mdl-29131091

ABSTRACT

BACKGROUND/AIMS: Apathy is one of the most frequent, disabling and difficult-to-treat symptoms that show up in many neurodegenerative disorders. The aim of this study was to assess and compare apathy profile in Parkinson's and Huntington's patients using the same comprehensive instruments to measure apathy, cognition and depressive symptoms. MATERIALS AND METHODS: We consecutively assessed Parkinson's disease (PD) and Huntington's disease (HD) patients recruited from a Movement Disorders Unit. In all patients, information related to demographics, clinical data, motor score (Movement Disorders Society-Unified Parkinson Disease Rating Scale; Unified Huntington Disease Rating Scale), cognition (Montreal Cognitive Assessment scale), depressive symptoms (Beck Depression Inventory II) and apathy (Apathy Evaluation Scale - clinical version) was collected. Patients with dementia or major depression according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revised criteria were excluded from the study. RESULTS: Seventy-five patients were enrolled, 45 with PD and 30 with HD. Apathy was present in 42.5% of PD patients and 51.7% of HD patients. In PD patients, apathy was associated with motor score, shorter duration of disease, lower dose of levodopa equivalent daily dose and depressive symptomatology, whereas in HD patients, apathy was related to disease duration, motor score and cognitive impairment. CONCLUSIONS: We found a similar prevalence of apathy in PD and HD patients but with different clinical correlations and different apathy domains involved, and this may warrant the development of different therapeutic approaches.


Subject(s)
Apathy , Huntington Disease/psychology , Parkinson Disease/psychology , Adult , Aged , Cross-Sectional Studies , Female , Humans , Huntington Disease/complications , Male , Middle Aged , Neuropsychological Tests , Parkinson Disease/complications , Prevalence
4.
Eur Neurol ; 80(1-2): 63-67, 2018.
Article in English | MEDLINE | ID: mdl-30227441

ABSTRACT

We performed a retrospective study with the aim of investigating the association between blood pressure (BP) variability in the first 24 h after ischemic stroke and functional outcome, regarding arterial recanalization status. A total of 674 patients diagnosed with acute stroke and treated with revascularization therapies were enrolled. Systolic and diastolic BP values of the first 24 h after stroke were collected and their variation quantified through standard deviation. Recanalization state was evaluated at 6 h and clinical outcome at 3 months was assessed by modified Rankin Scale. In multivariate analyses systolic BP variability in the first 24 h post-stroke showed an association with 3 months clinical outcome in the whole population and non-recanalyzed patients. In recanalyzed patients, BP variability did not show a significant association with functional outcome.


Subject(s)
Blood Pressure/physiology , Endovascular Procedures/methods , Stroke/physiopathology , Stroke/therapy , Treatment Outcome , Aged , Aged, 80 and over , Brain Ischemia/physiopathology , Brain Ischemia/therapy , Female , Humans , Male , Middle Aged , Multivariate Analysis , Recovery of Function , Retrospective Studies
5.
Stroke ; 47(6): 1571-6, 2016 06.
Article in English | MEDLINE | ID: mdl-27118796

ABSTRACT

BACKGROUND AND PURPOSE: Historical stroke cohorts reported a U- or J-shaped relationship between blood pressure (BP) and clinical outcome. However, these studies predated current revascularization strategies, disregarding the recanalization state of the affected arterial territory. We aimed to investigate the relationship between BP in the first 24 hours after ischemic stroke and clinical outcome in patients submitted to intravenous or intra-arterial recanalization treatments. METHODS: Consecutive patients with acute stroke treated with intravenous thrombolysis or intra-arterial therapies were enrolled in a retrospective cohort study. BP was measured on regular intervals throughout day and night during the first 24 hours after stroke onset. The mean systolic BP and diastolic BP during the first 24 hours post stroke were calculated. Recanalization was assessed at 6 hours by transcranial color-coded Doppler, angiography, or angio-computed tomography. Functional outcome was assessed at 3 months by modified Rankin Scale. Linear and quadratic multivariate regression models were performed to determine associations between BP and functional outcome for the whole population and recanalyzed and nonrecanalyzed patients. RESULTS: We included 674 patients; mean age was 73.28 (SD, 11.50) years. Arterial recanalization was documented in 355 (52.70%) patients. In multivariate analyses, systolic BP and diastolic BP in the first 24 hours post stroke show a J-shaped relationship with functional outcome in the total population and in the nonrecanalyzed patients. Recanalyzed patients show a linear association with functional outcome (systolic BP: odds ratio, 1.015; 95% confidence interval, 1.007-1.024; P=0.001; R(2) change=0.001; P=0.412 and diastolic BP: odds ratio, 1.019; 95% confidence interval, 1.004-1.033; P=0.012; R(2) change<0.001; P=0.635). CONCLUSIONS: Systemic BP in the first 24 hours after ischemic stroke influences 3-month clinical outcome. This association is dependent on the revascularization status.


Subject(s)
Blood Pressure/physiology , Brain Ischemia/therapy , Outcome Assessment, Health Care/methods , Registries , Stroke/therapy , Aged , Aged, 80 and over , Brain Ischemia/diagnostic imaging , Brain Ischemia/physiopathology , Endovascular Procedures , Female , Fibrinolytic Agents/therapeutic use , Humans , Male , Middle Aged , Plasminogen Activators/therapeutic use , Retrospective Studies , Stroke/diagnostic imaging , Stroke/physiopathology , Thrombolytic Therapy
6.
Eur Neurol ; 76(5-6): 252-255, 2016.
Article in English | MEDLINE | ID: mdl-27750247

ABSTRACT

BACKGROUND: The diagnosis of Parkinson's disease (PD) can sometimes be a challenge in the early stages of the disease. Both transcranial sonography (TCS) and DaTSCAN are recommended as auxiliary examinations for the differential diagnosis of PD; however, only few data exist regarding their diagnostic accuracy in the early stage of PD and essential tremor (ET). METHODS: We evaluated patients with clinically suspected diagnosis of PD at early stages (Hoehn and Yahr ≤2) or ET. All patients underwent DaTSCAN and TCS with a maximum interval of 6 months. Final diagnosis was established after 1-year follow-up. RESULTS: From the 63 patients recruited, 3 were excluded due to transcranial insonability and 2 for uncertain clinical diagnosis. The final clinical diagnosis was ET in 44.8% and PD in 55.2%. Compared to clinical diagnosis of PD, TCS had a sensitivity of 87.5% and specificity of 96.2%; DaTSCAN sensitivity was 84.4% and specificity was 96.2%. Both diagnostic tests demonstrated a substantial level of agreement (Cohen's kappa coefficient: 0.83, 95% CI 0.68-0.97, p < 0.001). CONCLUSION: TCS and DaTSCAN have similar diagnostic accuracy for the diagnosis of early stage PD versus ET.


Subject(s)
Parkinson Disease/diagnostic imaging , Tomography, Emission-Computed, Single-Photon/methods , Ultrasonography, Doppler, Transcranial/methods , Diagnosis, Differential , Essential Tremor/diagnostic imaging , Humans , Nortropanes , Sensitivity and Specificity
7.
Innov Clin Neurosci ; 20(10-12): 35-39, 2023.
Article in English | MEDLINE | ID: mdl-38193103

ABSTRACT

Objective: The advent of next-generation sequencing (NGS) enabled the detection of low-level brain somatic variants in postsurgical tissue of focal cortical dysplasia (FCD). The genetic background of FCD Type I remains elusive, while the mammalian target of rapamycin (mTOR) pathway seems to have a relevant role in the pathogenesis of FCD Type II. Our goal was to uncover information on the molecular basis of FCD, performing whole genome sequencing (WGS) in postsurgical tissue to detect candidate brain-specific somatic variants, and evaluate their clinical significance. Design: WGS was performed using paired peripheral venous blood and postsurgical pathological brain deoxyribonucleic acid (DNA) samples. Libraries were prepared using the Roche KAPA HyperPrep polymerase chain reaction (PCR) free library preparation kit. Paired-end 150bp reads were generated on the Illumina NovaSeq platform. The FASTQ files were processed using the nf-core sarek pipeline (version 3.0) to call somatic variants, which were then annotated with ANNOVAR. A screening strategy was applied to obtain relevant variants. Results: Two female patients with drug-resistant epilepsy due to FCD who underwent surgical treatment were included. Regarding neuropathological diagnosis, one patient had FCD Type Ia and the other had FCD Type IIa. Five somatic nonsynonymous single nucleotide variants (SNVs) were detected using WGS, three in FCD Ia tissue (WDR24 p.Trp259Gly; MICAL1 p.Lys1036Arg; and KATNB1 p.Leu566Ile) and two in FCD IIa tissue (MATN4 p.Phe91Val and ANKRD6 p.His386Gln). All variants were predicted to be potentially pathogenic by at least two different tools. However, they were classified as variants of uncertain significance (VUS) according to the American College of Medical Genetics and Genomics (ACMG) criteria. Conclusion: Brain-specific somatic missense variants were identified by NGS in new candidate genes (WDR24, MICAL1, KATNB1, MATN4, and ANKRD6) using postsurgical FCD tissue, which may contribute to further understanding of the genetic background of FCD. All the reported genes were previously related to epilepsy and/or malformations of central nervous system (CNS) and cortical development. However, the pathogenicity assessment of these variants and, consequently, their impact on clinical practice still poses an important challenge.

8.
Acta Med Port ; 36(4): 229-235, 2023 Apr 03.
Article in English | MEDLINE | ID: mdl-36108335

ABSTRACT

INTRODUCTION: Over recent decades, brain resection for drug-resistant epilepsy has proven to be a valuable treatment option. The histopathological classification was of paramount value for patient management. The aims of this study were to characterize our resective epilepsy surgical series including the histopathological diagnoses and to understand the differences in clinical practice between two different periods of our epilepsy surgical programme. MATERIAL AND METHODS: We performed a retrospective cohort study, including patients with drug-resistant epilepsy that underwent resective surgery between 1997 and 2021 in the Coimbra University Hospital Centre. Histopathological diagnoses were classified into seven major conventional categories. For comparison purposes, the cohort was divided into two consecutive periods of 12 years. RESULTS: A total of 259 patients were included, from which 228 (88%) were adults at the time of surgery. The median disease duration prior to surgery was 14 (interquartile range 23) years. Fifty-five (21%) patients performed pre-surgical invasive work-up. The temporal lobe was the most frequently operated region (73%). Major and minor post-surgical complications were identified in 21 (8%) patients. A reduction in the number of antiepileptic drugs was possible in 96 (37%) patients after surgery. The most common histopathological diagnosis was hippocampal sclerosis, but among children it was long-term epilepsy associated tumour. Long-term epilepsy associated tumours, hippocampal sclerosis and vascular malformations had the best post-operative outcomes. Malformations of cortical development and glial scars had the worst outcomes. Regarding differences between the two periods, the absolute number of operated patients increased (119 versus 140), and the age at surgery was higher in the second period (p = 0.04). The number of malformations of cortical development increased (p = 0.01), but the number of other tumours (p = 0.01) and specimens with no lesion (p = 0.03) decreased in the same period. CONCLUSION: This study is in line with contemporaneous research, reinforcing the previous knowledge on the underlying structural aetiologies, clinical practice, and surgical outcomes over more than two decades of experience. Our data provide realistic expectations about epilepsy surgery and highlight the need for further improvements in diagnosis and treatment paradigm for people with chronic epilepsy.


Introdução: Nas últimas décadas, a cirurgia ressectiva demonstrou ser uma opção valiosa no tratamento da epilepsia farmacorresistente. A classificação histopatológica foi de grande importância na orientação do doente. Os objetivos deste estudo foram caracterizar a nossa série de cirurgia de epilepsia ressectiva incluindo os diagnósticos histopatológicos, e compreender as diferenças na prática clínica entre dois períodos diferentes do programa de cirurgia da epilepsia. Material e Métodos: Realizou-se um estudo de coorte retrospetivo, incluindo doentes com epilepsia farmacorresistente submetidos a cirurgia ressectiva entre 1997 e 2021 no Centro Hospitalar e Universitário de Coimbra. Os diagnósticos histopatológicos foram classificados em sete categorias. Para análise comparativa, a coorte foi dividida em dois períodos consecutivos de 12 anos. Resultados: Um total de 259 doentes foram incluídos, sendo 228 (88%) adultos aquando da cirurgia. A mediana da duração da doença antes da cirurgia foi de 14 (amplitude interquartil 23) anos. Cinquenta e cinco (21%) doentes realizaram investigação invasiva pré-cirúrgica. O lobo temporal foi a região mais frequentemente operada (73%). Complicações pós-cirúrgicas major e minor foram identificadas em 21 (8%) doentes. Uma redução no número de antiepiléticos foi observada em 96 (37%) doentes após a cirurgia. O diagnóstico histopatológico mais comum foi a esclerose do hipocampo, mas nas crianças foi o tumor associado a epilepsia de longa duração. Tumores associados a epilepsia de longa duração, esclerose do hipocampo e malformações vasculares tiveram os melhores resultados pós-operatórios. Malformações do desenvolvimento cortical e cicatrizes gliais tiveram os piores resultados. Relativamente às diferenças entre os dois períodos, o número absoluto de doentes operados aumentou (119 versus 140), e a idade aquando da cirurgia foi maior no segundo período (p = 0,04). O número de malformações do desenvolvimento cortical aumentou (p = 0,01), mas o número de outros tumores (p = 0,01) e amostras sem lesão (p = 0,03) diminuiu no mesmo período. Conclusão: Este estudo está de acordo com a literatura atual, reforçando o conhecimento prévio sobre as etiologias estruturais, prática clínica e resultados cirúrgicos ao longo de mais de duas décadas de experiência. Os dados analisados fornecem expectativas realistas sobre a cirurgia de epilepsia e destacam a necessidade de melhorias no paradigma de diagnóstico e tratamento destes doentes.


Subject(s)
Drug Resistant Epilepsy , Hippocampal Sclerosis , Neurosurgical Procedures , Adult , Child , Humans , Drug Resistant Epilepsy/diagnosis , Drug Resistant Epilepsy/pathology , Drug Resistant Epilepsy/surgery , Hippocampal Sclerosis/diagnosis , Hippocampal Sclerosis/pathology , Hippocampal Sclerosis/surgery , Retrospective Studies , Treatment Outcome
9.
Acta Neurol Belg ; 122(1): 123-128, 2022 Feb.
Article in English | MEDLINE | ID: mdl-33905106

ABSTRACT

Nervous system (NS) affection may occur in Eosinophilic Granulomatosis with Polyangiitis (EGPA), but its clinical manifestations and pathophysiology are rarely described. Our aims are to characterize central and peripheral NS (CNS/PNS) involvement and compare biological markers in EGPA patients with and without neurological manifestations. Retrospective observational study, including EGPA patients with and without neurological manifestations. Demographics, clinical data, and immunological markers were analyzed. Descriptive and inferential statistics were performed. Sixteen patients were included; 11 (68.8%) of whom were male, with a mean age of 63.38 years; 8 with (Group 1) and 8 without (Group 2) neurological findings. Neurological impairment preceded EGPA diagnosis in 5 patients, and occurred during follow-up in 3 patients after a median of 4.0 years. CNS manifestations observed were stroke (n = 2), bilateral central retinal artery occlusion (n = 1), and compressive dorsal myelopathy due to extradural granulation tissue (n = 1). PNS manifestations were axonal polyneuropathy (n = 3), sensorineural hearing loss (n = 3), and multiplex mononeuropathy (n = 1). Two patients had both PNS and CNS involvement. There were no statistical differences regarding biological markers [eosinophil count, myeloperoxidase (MPO) antibodies titers] between the 2 groups. One patient from Group 1 was unresponsive to treatment and permanent neurological sequelae were observed in 7 cases. EGPA-related NS involvement can be heterogeneous and is responsible for long-term sequelae. In our sample, the main neurological scenarios were peripheral neuropathy, VIII cranial nerve neuropathy, ischemic lesions and compressive myelopathy. Patients with and without neurological manifestations did not differ in eosinophilic count and MPO titer.


Subject(s)
Churg-Strauss Syndrome/diagnosis , Granulomatosis with Polyangiitis/diagnosis , Aged , Female , Humans , Male , Middle Aged , Peripheral Nervous System Diseases/complications , Retrospective Studies
10.
J Multidiscip Healthc ; 15: 1469-1480, 2022.
Article in English | MEDLINE | ID: mdl-35860622

ABSTRACT

Tuberous sclerosis complex (TSC) is a rare genetic disease of autosomal dominant transmission that, in most cases, results from the presence of pathogenic variants of the TSC1 or TSC2 genes, encoding hamartin and tuberin, respectively. It is a multisystemic disease, affecting most frequently the brain, skin, kidney, and heart. The wide variety of possible clinical manifestations, given this multisystem dimension, makes the follow-up of patients with TSC an exercise of multidisciplinarity. In fact, these patients may require the intervention of various medical specialties, which thus have to combine their efforts to practice a medicine that is truly holistic. The past few years have witnessed a dramatic leap not only in the diagnosis and management of TSC patients, with standard monitoring recommendations, but also in the therapeutic field, with the use of mTORC1 inhibitors. In this article, we review the clinical manifestations associated with TSC, as well as the treatment and follow-up strategies that should be implemented, from a multidisciplinary perspective.

11.
Epileptic Disord ; 23(2): 291-298, 2021 Apr 01.
Article in English | MEDLINE | ID: mdl-33875410

ABSTRACT

The epilepsy-related risk factors for vitamin D deficiency, particularly the use of enzyme-inducing antiepileptic drugs (EIAEDs), and how to treat vitamin D deficiency in patients with epilepsy remain unclear. Our aims were to explore risk factors and the influence of EAIEDs in vitamin D status and to determine the efficacy of a daily dose of oral cholecalciferol (vitamin D3) in epileptic patients with vitamin D deficiency. Clinical data were collected and 25-hydroxyvitamin D (25(OH)D) serum levels were measured. All patients with vitamin D deficiency (25(OH)D ≤20 ng/mL) or insufficiency (25(OH)D from 21-29 ng/mL) were treated with 6,670 IU/day cholecalciferol for eight weeks and 25(OH)D was then remeasured. Descriptive and inferential statistics were employed. A total of 92 patients (44.6% males), with mean age of 41.0±14.8 years, were included. Measurements of 25(OH)D revealed that 79.3% patients had abnormal levels: 56.5% were vitamin D deficient and 22.8% were vitamin D insufficient. The statistically significant risk factors for vitamin D deficiency identified were: number of AEDs, treatment with EIAEDs, low sun exposure, high body mass index (BMI) and a high frequency of epileptic seizures. After treatment, 25(OH)D mean level increased by 98.99% (regardless of EIAED use or being overweight). In our sample, more than half of the adults with epilepsy showed 25(OH)D deficiency. Patients on EIAEDs had lower 25(OH)D levels. A daily dose of 6,670 IU cholecalciferol successfully led to the correction of 25(OH)D levels. A higher dose in obese patients or in patients taking EIAEDs may not be warranted and this should be considered in future guidelines for routine vitamin D deficiency treatment.


Subject(s)
Epilepsy , Vitamin D Deficiency , Adult , Cholecalciferol , Epilepsy/drug therapy , Epilepsy/etiology , Female , Humans , Male , Middle Aged , Portugal , Vitamin D , Vitamin D Deficiency/complications , Vitamin D Deficiency/drug therapy , Vitamin D Deficiency/epidemiology , Vitamins
12.
Oxf Med Case Reports ; 2021(5): omab027, 2021 May.
Article in English | MEDLINE | ID: mdl-34055363

ABSTRACT

Germline and 2-hit brain somatic variants in DEPDC5 gene, a negative regulator of the mammalian target of rapamycin (mTOR) pathway, are increasingly recognized in patients with focal cortical dysplasia (FCD). Next-generation targeted sequencing identified a heterozygous germline variant in DEPDC5 gene (c.3241A>C, p.Thr1081Pro), classified as of unknown significance, in a patient with clinical features compatible with DEPDC5 phenotype (FCD, focal epilepsy, attention-deficit/hyperactivity disorder and borderline intellectual functioning). This missense variant has previously been reported in two other epileptic patients. Although interpretation of missense variants remains a challenge, DEPDC5 variants in patients with FCD and epilepsy cannot be neglected. Null variants were the most frequently reported in FCD patients, but missense variants have been described as well. The recognition of DEPDC5 phenotype and the appropriate interpretation of the detected variants are essential, since it may have important treatment implications in the near future, namely the use of mTOR inhibitors.

13.
Clin Case Rep ; 8(1): 61-64, 2020 Jan.
Article in English | MEDLINE | ID: mdl-31998487

ABSTRACT

Epilepsy should be suspected in patients with Stiff-person syndrome and new onset paroxysmal episodes. Musicogenic epilepsy may be a manifestation of anti-GAD-Ab spectrum, supporting an autoimmune workup in these patients. Appropriate treatment is not well established, and immunotherapy should be considered in patients with only partial response to antiepileptic drugs.

14.
Front Neurosci ; 14: 580357, 2020.
Article in English | MEDLINE | ID: mdl-33551717

ABSTRACT

Introduction: Focal cortical dysplasias (FCDs) are a group of malformations of cortical development that constitute a common cause of drug-resistant epilepsy, often subjected to neurosurgery, with a suboptimal long-term outcome. The past few years have witnessed a dramatic leap in our understanding of the molecular basis of FCD. This study aimed to provide an updated review on the genomic and epigenetic advances underlying FCD etiology, to understand a genotype-phenotype correlation and identify priorities to lead future translational research. Methods: A scoping review of the literature was conducted, according to previously described methods. A comprehensive search strategy was applied in PubMed, Embase, and Web of Science from inception to 07 May 2020. References were screened based on title and abstract, and posteriorly full-text articles were assessed for inclusion according to eligibility criteria. Studies with novel gene variants or epigenetic regulatory mechanisms in patients that underwent epilepsy surgery, with histopathological diagnosis of FCD type I or II according to Palmini's or the ILAE classification system, were included. Data were extracted and summarized for an overview of evidence. Results: Of 1,156 candidate papers, 39 met the study criteria and were included in this review. The advent of next-generation sequencing enabled the detection in resected FCD tissue of low-level brain somatic mutations that occurred during embryonic corticogenesis. The mammalian target of rapamycin (mTOR) signaling pathway, involved in neuronal growth and migration, is the key player in the pathogenesis of FCD II. Somatic gain-of-function variants in MTOR and its activators as well as germline, somatic, and second-hit mosaic loss-of-function variants in its related repressors have been reported. However, the genetic background of FCD type I remains elusive, with a pleomorphic repertoire of genes affected. DNA methylation and microRNAs were the two epigenetic mechanisms that proved to have a functional role in FCD and may represent molecular biomarkers. Conclusion: Further research into the possible pathogenic causes of both FCD subtypes is required, incorporating single-cell DNA/RNA sequencing as well as methylome and proteomic analysis. The collected data call for an integrated clinicopathologic and molecular genetic diagnosis in current practice not only to improve diagnostic accuracy but also to guide the development of future targeted treatments.

18.
Br J Ophthalmol ; 102(1): 102-108, 2018 01.
Article in English | MEDLINE | ID: mdl-28487376

ABSTRACT

BACKGROUND/AIMS: Neurodegeneration with brain iron accumulation (NBIA) type I is a rare disease that can be divided into a classical or atypical variant, according to age of onset and clinical pattern. Neuro-ophthalmological involvement has been documented in the classical variant but only anecdotically in the atypical variant. We sought to describe the visual and ocular motor function in patients with atypical form of NBIA type I. METHODS: Cross-sectional study, including patients with genetically confirmed NBIA type I and classified as atypical variant, who underwent ophthalmological examination with best corrected visual acuity (BCVA), optical coherence tomography (OCT), fundus autofluorescence (FAF), electroretinography (ERG), visual evoked potentials (VEP) and video-oculography. RESULTS: Seven patients with a mean BCVA of 0.12±0.14 logMAR were included. Only two patients showed structural evidence of advanced retinopathy in OCT and FAF, and there were no cases of optic atrophy. ERG data, however, showed abnormal scotopic and/or photopic responses in all patients. VEP were normal in all three patients. Ocular fixation was markedly unstable (eg, increased rate of saccadic pulses) in the majority of patients (5). Additional mild ocular motor disturbances included low gain pursuit (2), hypermetric saccades (1), low gain optokinetic (2) and caloric and rotatory responses (3). CONCLUSION: Functional retinal changes associated with marked instability of ocular fixation should be included in the clinical spectrum of NBIA, particularly in the atypical form.


Subject(s)
Evoked Potentials, Visual/physiology , Eye Movements/physiology , Iron Metabolism Disorders/complications , Neuroaxonal Dystrophies/complications , Ocular Motility Disorders/physiopathology , Retina/physiopathology , Retinal Diseases/physiopathology , Visual Acuity , Adult , Cross-Sectional Studies , Electroretinography , Female , Fluorescein Angiography , Fundus Oculi , Humans , Iron Metabolism Disorders/diagnosis , Iron Metabolism Disorders/physiopathology , Male , Middle Aged , Neuroaxonal Dystrophies/diagnosis , Neuroaxonal Dystrophies/physiopathology , Ocular Motility Disorders/diagnosis , Ocular Motility Disorders/etiology , Retina/diagnostic imaging , Retinal Diseases/diagnosis , Retinal Diseases/etiology , Tomography, Optical Coherence , Young Adult
19.
Neuroradiol J ; 31(5): 456-463, 2018 Oct.
Article in English | MEDLINE | ID: mdl-29663853

ABSTRACT

Background Cerebral edema is frequent in patients with acute ischemic stroke (AIS) who undergo reperfusion therapy and is associated with high mortality. The impact of collateral pial circulation (CPC) status on the development of edema has not yet been determined. Methods We studied consecutive patients with AIS and documented M1-middle cerebral artery (MCA) and/or distal internal carotid artery (ICA) occlusion who underwent reperfusion treatment. Edema was graded on the 24-hour non-contrast computed tomography (NCCT) scan. CPC was evaluated at the acute phase (≤6 hours) by transcranial color-coded Doppler, angiography and/or CT angiography. We performed an ordinal regression model for the effect of CPC on cerebral edema, adjusting for age, baseline National Institutes of Health Stroke Scale, Alberta Stroke Program Early Computed Tomography Score (ASPECTS) on admission, NCCT, parenchymal hemorrhagic transformation at 24 hours and complete recanalization at six hours. Results Among the 108 patients included, 49.1% were male and mean age was 74.2 ± 11.6 years. Multivariable analysis showed a significant association between cerebral edema and CPC status (OR 0.22, 95% CI 0.08-0.59, p = 0.003), initial ASPECTS (OR 0.72, 95% CI 0.57-0.92, p = 0.007) and parenchymal hemorrhagic transformation (OR 23.67, 95% CI 4.56-122.8, p < 0.001). Conclusions Poor CPC is independently associated with greater cerebral edema 24 hours after AIS in patients who undergo reperfusion treatment.


Subject(s)
Brain Edema/diagnostic imaging , Brain Ischemia/physiopathology , Collateral Circulation , Pia Mater/blood supply , Stroke/physiopathology , Aged , Brain/diagnostic imaging , Brain/physiopathology , Brain Edema/etiology , Brain Edema/physiopathology , Brain Ischemia/complications , Brain Ischemia/diagnostic imaging , Brain Ischemia/therapy , Carotid Artery Diseases/complications , Carotid Artery Diseases/diagnostic imaging , Carotid Artery Diseases/physiopathology , Carotid Artery Diseases/therapy , Carotid Artery, Internal , Cerebral Arterial Diseases/complications , Cerebral Arterial Diseases/diagnostic imaging , Cerebral Arterial Diseases/physiopathology , Cerebral Arterial Diseases/therapy , Female , Humans , Male , Multivariate Analysis , Pia Mater/physiopathology , Regression Analysis , Stroke/complications , Stroke/diagnostic imaging , Stroke/therapy , Time Factors , Tomography, X-Ray Computed , Treatment Outcome
20.
Acta Med Port ; 30(5): 395-401, 2017 May 31.
Article in English | MEDLINE | ID: mdl-28865504

ABSTRACT

INTRODUCTION: Parkinson's disease has a significant impact in quality of life, which can be assessed with 39-item Parkinson's Disease Questionnaire and Parkinson's Disease Quality of Life Questionnaire. This study aimed to evaluate the reliability and validity of these scales in Portuguese patients. MATERIAL AND METHODS: Reliability was assessed through internal consistency (Cronbach's alpha) and reproducibility (intraclass correlation coefficient). Regarding construct validity, we performed one-way analysis of variance across different groups according to modified Hoehn and Yahr scale. For criterion validity, we compared both scales with each other and with the Short Form 36-item Health Survey. RESULTS: In a total of 100 patients with Parkinson's disease, Cronbach's alpha ranged for 39-item Parkinson's Disease Questionnaire between 0.66 - 0.98, and for Parkinson's Disease Quality of Life Questionnaire, between 0.78 - 0.98. Intraclass correlation coefficient for 39-item Parkinson's Disease Questionnaire ranged between 0.49 - 0.96, and for Parkinson's Disease Quality of Life Questionnaire, ranged between 0.65 - 0.96. Both scales showed, in general, capacity to discriminate differences among patients in the different stages of disease. The scales presented moderate to strong magnitude correlations with some Short Form 36-item Health Survey domains. DISCUSSION: Cronbach's alpha coefficients for most domains were satisfactory. Overall, it has been demonstrated good reproducibility, as well as construct and criterion validity. CONCLUSION: The Portuguese versions of both scales showed to be valid and reliable.


Introdução: A doença de Parkinson tem um impacto significativo na qualidade de vida, podendo ser medido através do Questionário de Doença de Parkinson-39 e do Questionário de Qualidade de Vida na Doença de Parkinson. O objectivo deste estudo foi avaliar a fiabilidade e validade destas escalas em doentes portugueses. Material e Métodos: A fiabilidade foi avaliada através da consistência interna (alfa de Cronbach) e reprodutibilidade (coeficiente de correlação intraclasse). Relativamente à validade de construção, realizou-se uma análise de variância entre diferentes grupos, de acordo com a escala modificada Hoehn and Yahr. Para a validade de critério comparam-se ambas as escalas entre si e com o Short Form 36-item Health Survey. Resultados: Num total de 100 doentes com doença de Parkinson, o alfa de Cronbach variou para o Questionário de Doença de Parkinson-39 entre 0,66 ­ 0,98, e para o Questionário de Qualidade de Vida na Doença de Parkinson, entre 0,78 ­ 0,98. O coeficiente de correlação intraclasse para o Questionário de Doença de Parkinson-39 variou entre 0,49 ­ 0,96, e para o Questionário de Qualidade de Vida na Doença de Parkinson, variou entre 0,65 ­ 0,96. Ambas as escalas demonstraram, em geral, capacidade de discriminação entre doentes em diferentes estadios da doença. As escalas apresentaram correlações de magnitude moderada a forte com alguns domínios do Short Form 36-item Health Survey. Discussão: Os coeficientes do alfa de Cronbach foram satisfatórios para a maioria dos domínios. No geral, demonstrou-se boa reprodutibilidade, assim como validade de construção e critério. Conclusão: As versões portuguesas de ambas as escalas demonstraram ser fiáveis e válidas.


Subject(s)
Diagnostic Self Evaluation , Parkinson Disease , Quality of Life , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Parkinson Disease/diagnosis , Psychometrics , Reproducibility of Results
SELECTION OF CITATIONS
SEARCH DETAIL